-
Electronic (PDF)
-
Site License
-
Enterprisewide
4-Antibody AG - Product Pipeline Review - 2012
Global Markets Direct, July 2012, Pages: 34
4-Antibody AG – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “4-Antibody AG - Product Pipeline Review - 2012” provides data on the 4-Antibody AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, 4-Antibody AG’s corporate website, SEC filings, investor presentations and featured press releases, both from 4-Antibody AG and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- 4-Antibody AG - Brief 4-Antibody AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of 4-Antibody AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of 4-Antibody AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the 4-Antibody AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate 4-Antibody AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of 4-Antibody AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the 4-Antibody AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with 4-Antibody AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of 4-Antibody AG and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of 4-Antibody AG; 4-Antibody AG - Key Therapeutics; 4-Antibody AG - Pipeline Overview and Promising Molecules; 4-Antibody AG - News; 4-Antibody AG - Latest Updates; 4-Antibody AG - Pipeline; 4-Antibody AG - Discontinued/Dormant Projects
2
List of Tables 4
List of Figures 4
4-Antibody AG Snapshot 5
4-Antibody AG Overview 5
Key Information 5
Key Facts 5
4-Antibody AG – Research and Development Overview 6
Key Therapeutic Areas 6
4-Antibody AG – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
4-Antibody AG – Pipeline Products Glance 10
4-Antibody AG – Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
4-Antibody AG – Drug Profiles 12
4Ab-028 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Antibodies to CXCR3 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Antibody Targeting GITR 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Antibody Targeting OX40 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Antibody Targeting TIM3 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Drug For AutoImmune Disorders And Inflammation 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
4-Antibody AG – Pipeline Analysis 19
4-Antibody AG – Pipeline Products by Therapeutic Class 19
4-Antibody AG – Pipeline Products By Mechanism of Action 20
4-Antibody AG – Locations And Subsidiaries 21
Head Office 21
Financial Deals Landscape 22
4-Antibody AG, Deals Summary 22
4-Antibody AG, Pharmaceuticals & Healthcare, Deal Details 23
Venture Financing 23
4-Antibody Secures Additional $13.7 Million Through Series A Financing Round 23
4-Antibody Secures $0.43 Million In Equity Financing 25
4-Antibody Secures $2.15 Million In Seed Financing 26
Partnerships 28
4-Antibody Enters Into Co-Development Agreement With Human Genome Sciences 28
4-Antibody Enters Into Co-Development Agreement With Ludwig Institute 29
4-Antibody Enters Into Long-Term Collaboration Agreement With Boehringer Ingelheim 31
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34
List of Tables
4-Antibody AG, Key Information 5
4-Antibody AG, Key Facts 5
4-Antibody AG – Pipeline by Indication, 2012 7
4-Antibody AG – Pipeline by Stage of Development, 2012 8
4-Antibody AG – Monotherapy Products in Pipeline, 2012 9
4-Antibody AG – Pre-Clinical, 2012 10
4-Antibody AG – Discovery, 2012 11
4-Antibody AG – Pipeline By Therapeutic Class, 2012 19
4-Antibody AG – Pipeline Products By Mechanism of Action, 2012 20
4-Antibody AG, Deals Summary 22
4-Antibody Secures Additional $13.7 Million Through Series A Financing Round 23
4-Antibody Secures $0.43 Million In Equity Financing 25
4-Antibody Secures $2.15 Million In Seed Financing 26
4-Antibody Enters Into Co-Development Agreement With Human Genome Sciences 28
4-Antibody Enters Into Co-Development Agreement With Ludwig Institute 29
4-Antibody Enters Into Long-Term Collaboration Agreement With Boehringer Ingelheim 31
List of Figures
4-Antibody AG – Pipeline by Indication, 2012 7
4-Antibody AG – Pipeline by Stage of Development, 2012 8
4-Antibody AG – Monotherapy Products in Pipeline, 2012 9
4-Antibody AG – Pipeline By Therapeutic Class, 2012 19
4-Antibody AG - Pipeline Products By Mechanism of Action, 2012 20
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
